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Introduction: This randomized open-label phase II study evaluated 
the efficacy, safety, and tolerability of pazopanib in combination with 
pemetrexed compared with the standard cisplatin/pemetrexed dou-
blet in patients with previously untreated, advanced, nonsquamous 
non–small-cell lung cancer.
Methods: Patients were randomized (2:1 ratio) to receive peme-
trexed 500 mg/m2 intravenously once every 3 weeks plus either oral 
pazopanib 800 mg daily or cisplatin 75 mg/m2 intravenously once 
every 3 weeks up to six cycles. All patients received folic acid, vita-
min B12, and steroid prophylaxis. The primary endpoint was pro-
gression-free survival (PFS).
Results: The study was terminated after 106 of 150 patients were 
randomized due to a higher incidence of adverse events leading to 
withdrawal from the study and severe and fatal adverse events in the 
pazopanib/pemetrexed arm than in the cisplatin/pemetrexed arm. At 
the time enrolment was discontinued, there were three fatal adverse 
events in the pazopanib/pemetrexed arm, including ileus, tumor 
embolism, and bronchopneumonia/sepsis. Treatment with pazo-
panib/pemetrexed was discontinued resulting in more PFS data cen-
sored for patients in the pazopanib/pemetrexed arm than those in the 
cisplatin/pemetrexed arm. There was no statistically significant dif-
ference between the pazopanib/pemetrexed and cisplatin/pemetrexed 
arms for PFS (median PFS, 25.0 versus 22.9 weeks, respectively; 
hazard ratio = 0.75; 95% confidence interval, 0.43%–1.28%; p = 
0.26) or objective response rate (23% versus 34%, respectively; 95% 
confidence interval, –30.6% to 7.2%; p = 0.21).
Conclusion: The combination of pazopanib/pemetrexed in first-line 
treatment of non–small-cell lung cancer showed some antitumor 
activity but had unacceptable levels of toxicity.
Key Words: Non–small-cell lung cancer, Pazopanib, Pemetrexed, 
Cisplatin.
(J Thorac Oncol. 2013;8: 1529–1537)
The role of chemotherapy in the treatment of advanced non–small-cell lung cancer (NSCLC) remains mainly pal-
liative, although platinum-based doublet chemotherapy has 
been proven to significantly improve survival, disease-related 
symptoms, and quality of life.1,2 In this context, the addition of 
cisplatin to a single cytotoxic agent confers an undeniable but 
moderate benefit for chemotherapy-naive patients with inop-
erable NSCLC in randomized studies.3,4 Thus, the trade-off 
between activity and chemotherapy-related side effects must 
always be adequately considered in the individual patient.
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Few randomized trials have directly compared plati-
num-based regimens with nonplatinum combinations, but 
they have generally demonstrated comparable response rates 
and median survival times.5–9 Although platinum-free dou-
blets including third-generation agents have been proven to 
be equally active,10 clinicians do not commonly use these 
regimens in daily clinical practice unless platinum agents 
are contraindicated. The addition of an antiangiogenic mono-
clonal antibody to a standard cytotoxic doublet provides an 
additional benefit in terms of disease control11,12 and overall 
survival (OS)12 in selected patients with metastatic NSCLC.
Efforts to identify drugs that inhibit key pathways 
involved in the pathogenesis of cancer, such as angiogenesis, 
have also led to the development of multitargeted tyrosine 
kinase inhibitors (TKI) in the last decade. Pazopanib is a TKI 
of the vascular endothelial growth factor receptor (VEGFR), 
platelet-derived growth factor receptor, and stem cell growth 
factor receptor (c-KIT), and it is approved for the treatment of 
patients with advanced renal cell carcinoma13 and advanced 
soft-tissue sarcoma who have received prior chemotherapy.14 
Pazopanib has demonstrated activity in NSCLC, with 86% of 
patients with early-stage NSCLC who participated in a preop-
erative study experiencing volumetric reduction of their tumor 
after a median duration of 16 days treatment with single-agent 
pazopanib and with a modest toxicity profile.15
Pemetrexed is one of the most active cytotoxic agents 
used for nonsquamous NSCLC and is a potent inhibitor of 
thymidylate synthase16,17 and other folate-dependent enzymes, 
including dihydrofolate reductase and glycinamide ribonu-
cleotide formyl transferase.18 Pemetrexed currently has regu-
latory approval in combination with cisplatin for first-line 
treatment of malignant pleural mesothelioma19 and nonsqua-
mous NSCLC20 and as a single agent for second-line21 and 
maintenance treatment.22–24
Theoretically in NSCLC, the combination of pazopanib 
and pemetrexed had the premise for clinically meaningful ther-
apeutic activity coupled with a safe nonoverlapping toxicity 
profile, potentially better than platinum-based chemotherapy, 
based on the toxicity profile of each individual agent. A phase 
Ib study of the combination in patients with solid tumors iden-
tified a maximum tolerated dose of pazopanib 800 mg plus 
pemetrexed 500 mg/m2.25 To further explore the activity and 
the toxicity of this doublet, a randomized, multicenter phase II 
study was conducted in first-line patients with advanced non-
squamous NSCLC to compare the combination of pazopanib 
and pemetrexed versus cisplatin and pemetrexed.
PATIENTS AND METHODS
Patient Selection
Chemotherapy-naive patients with histologically or 
cytologically proven predominantly nonsquamous cell stage 
IIIB wet (with confirmed malignant pleural effusion) or stage 
IV NSCLC according to the 6th edition of Tumor, Node, 
Metastasis classification,26 at least 18 years of age, with an 
Eastern Cooperative Oncology Group performance status 
of 0 or 1, measurable disease as defined by the Response 
Evaluation Criteria in Solid Tumors 1.0,27 and a predicted life 
expectancy of at least 12 weeks were eligible. Prior surgery 
and/or localized irradiation for NSCLC were permitted at a 
minimum of 4 weeks before study entry. Patients with previ-
ously treated, clinically stable, central nervous system metas-
tases were eligible.
Patients were required to have adequate bone marrow, 
hepatic, and renal function. Exclusion criteria included poorly 
controlled hypertension; history of cerebrovascular accident, 
including transient ischemic attack, pulmonary embolism, or 
untreated deep venous thrombosis within the past 6 months; 
recent hemoptysis; and known endobronchial lesions.
This study was conducted in accordance with the 
Declaration of Helsinki and the International Conference on 
Harmonization Good Clinical Practice guidelines and was 
approved by each participating institution’s independent eth-
ics committee. All patients provided written informed consent 
before any study procedures were performed.
Study Design and Treatment
Eligible patients were randomly assigned (2:1 ratio) to 
receive either (1) pemetrexed 500 mg/m2 intravenously (IV) 
once every 3 weeks for a maximum of six cycles plus oral 
pazopanib (Votrient; GlaxoSmithKline, Research Triangle 
Park, NC) 800 mg once daily until completion of the com-
bination treatment and then as pazopanib monotherapy at 
800 mg once daily (until disease progression, unacceptable 
toxicities, or death) or (2) pemetrexed 500 mg/m2 IV plus 
cisplatin 75 mg/m2 IV once every 3 weeks for a maximum of 
six cycles. Patients were randomized in a 2:1 ratio to obtain 
sufficient data on the tolerability profile of the pazopanib/
pemetrexed combination. Patients on both arms received 
standard premedication for pemetrexed including dexa-
methasone (or equivalent corticosteroid), folic acid, and 
vitamin B12. Patients on the pemetrexed/cisplatin combina-
tion were allowed to receive single-agent pazopanib at the 
time of progression.
Dose modification guidelines for adverse events were 
prespecified. Cycle delays for pemetrexed or pemetrexed/
cisplatin or interruption of pazopanib treatment for up to 
14 days were permitted for recovery from adverse events. 
Concomitant supportive therapies, such as erythropoiesis-
stimulating agents or granulocyte colony-stimulating factors, 
were allowed according to the American Society of Clinical 
Oncology guidelines.28
A Safety Review Committee (SRC), independent of 
the study team, was established to monitor aggregated safety 
and efficacy data for each treatment arm on a monthly basis 
during the conduct of the study. Data reviews began after the 
first 10 patients in the study had completed the first cycle of 
treatment. The data reviewed by the SRC included all deaths 
(disease-related and fatal serious adverse events), serious 
adverse events, adverse events, study treatment discontinu-
ations, and laboratory investigations (including a targeted 
review of hematologic toxicity). The SRC was guided by the 
following criteria in recommending consideration of a study 
modification or study cessation: “Sufficient evidence to sug-
gest that the true risk of adverse outcomes (e.g., pulmonary 
hemorrhage, hepatotoxicity, or other adverse events) among 
patients in the test arm is in excess of that among control 
1531Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013 Study of Pazopanib in Combination with Pemetrexed
patients at a rate that significantly alters the risk-benefit ratio 
for the patients being treated.”
Initially, the SRC reported an increased frequency of 
severe (grade 3 and grade 4) neutropenia in the pazopanib/
pemetrexed arm compared with the cisplatin/pemetrexed arm 
and an imbalance in discontinuation rates of study treatment 
suggestive of broader toxicity in the pazopanib/pemetrexed 
arm. At this time, a total of four deaths were reported in the 
pazopanib/pemetrexed arm; three deaths were attributed to 
disease. As a result of the SRC findings, the protocol was 
amended (amendment 01) to reduce the starting dose of 
pazopanib from 800 to 600 mg daily in the pazopanib/peme-
trexed arm for all new patients enrolled in the study, and new 
and more stringent pazopanib dose modification guidelines 
for hematologic toxicity were implemented. After another 
month, the SRC reported an imbalance in deaths across the 
two treatment arms. As a result of this finding, the protocol 
was urgently amended (amendment 02) to stop new enrol-
ment in the study and patients being treated with pazopanib 
plus pemetrexed were taken off treatment. In amendment 
03, a decision was made not to reactivate enrolment in the 
study and to remove the requirement for posttreatment dis-
ease assessments and survival follow-up. The study remained 
open to enable patients receiving treatment with pazopanib 
monotherapy or with cisplatin/pemetrexed to complete their 
scheduled treatments.
Study Endpoints and Assessments
The primary efficacy endpoint was progression-free 
survival (PFS), defined as the interval between the date of 
randomization and the first occurrence of progressive disease 
or death. Secondary endpoints included OS, defined as the 
interval from the date of randomization to the date of death; 
objective response, defined as the percentage of patients (i.e., 
responders) who achieved either a complete response or par-
tial response as per Response Evaluation Criteria in Solid 
Tumors 1.0 criteria27 for at least 4 weeks at any time during 
randomized treatment; and safety and tolerability.
Disease assessments were repeated approximately 
every 6 weeks for the first 18 weeks and every 8 weeks there-
after until disease progression. Adverse events were graded 
according to the National Cancer Institute Common Toxicity 
Criteria, version 3.0.
Statistical Analysis
The study was designed as a descriptive study using the 
selection method.29 Using this design, with a sample size of 
150 patients, the probability of correctly selecting the pazo-
panib/pemetrexed regimen over the cisplatin/pemetrexed 
regimen based on an observed hazard ratio (HR) favoring the 
pazopanib/pemetrexed regimen was 86%.
Efficacy analyses were conducted on the intent-to-treat 
population, which comprised all patients who were random-
ized to receive treatment and were analyzed based on the 
assigned randomized treatment and not based on the actual 
treatment received (or not received). The safety population 
comprised all patients who had received at least one dose of 
each study drug in at least one cycle of treatment.
PFS and OS were summarized using Kaplan–Meier 
survival curves and compared between the treatment arms 
(pazopanib/pemetrexed versus cisplatin/pemetrexed) using 
an unstratified log-rank test. The Pike estimator30 of the treat-
ment HR based on the log-rank test was provided along with 
the corresponding 95% confidence interval (CI). Early dis-
continuation of enrolment compromises the power to detect 
differences in OS between the treatment arms. As a conse-
quence, the OS estimate should be interpreted with caution. 
Approximate 95% CIs for objective response rates (ORR) 
were calculated for each regimen. The treatment difference in 
the ORR and the approximate 95% CI was also calculated.
RESULTS
Patient Characteristics
Between July 09, 2009, and March 30, 2010, 106 of a 
planned 150 patients were randomly assigned in a 2:1 ratio to 
receive pazopanib/pemetrexed (n = 71) or cisplatin/pemetrexed 
(n = 35) (Figure 1); 103 of these patients received treatment.
After 62 patients were randomized to the pazopanib/
pemetrexed arm, the SRC recommended a reduction of the 
starting daily dose of pazopanib from 800 to 600 mg in the 
pazopanib/pemetrexed arm for all new patients randomized 
into the study due to an increased frequency of severe neu-
tropenia (grade 3 and grade 4) in the pazopanib combination 
arm compared with the control arm, as well as an imbalance 
in drug discontinuations (Figure 1). Only nine patients were 
randomized to this reduced-dose pazopanib/pemetrexed treat-
ment, eight of whom received treatment, before this combina-
tion treatment was permanently discontinued and enrolment 
into the study was halted by the SRC recommendation due to 
a detected imbalance in mortality between the treatment arms. 
These eight patients were not included in the efficacy analysis 
because of the small sample size and limited efficacy data.
Demographic and baseline characteristics were gen-
erally balanced for age, sex, race, and some disease-related 
characteristics between the pazopanib/pemetrexed and cis-
platin/pemetrexed arms; however, some imbalances were 
observed in baseline Eastern Cooperative Oncology Group 
performance status, history of tobacco use, and unintentional 
weight loss (Table 1).
Treatment
More patients in the cisplatin/pemetrexed arm com-
pleted the planned number of cycles of chemotherapy treat-
ment than those in the pazopanib/pemetrexed arm (Figure 1). 
Patients received a median total of four cycles (range, 1–6 
cycles) in the cisplatin/pemetrexed arm and three cycles 
(range, 1–6 cycles) in the pazopanib/pemetrexed arm. The 
median dose of pemetrexed was 500 mg/m2 in each treatment 
arm. In the pazopanib/pemetrexed arm, 61 patients received 
91% of the planned pazopanib dose of 800 mg daily. Fourteen 
patients received pazopanib monotherapy; 13 of these patients 
after completion of pazopanib/pemetrexed treatment and one 
patient after disease progression on cisplatin/pemetrexed 
(Figure 1). Because of the early discontinuation of the study, 
data on poststudy therapies were not systematically collected.
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Efficacy
Table 2 summarizes the investigator-assessed Kaplan–
Meier estimates for PFS. There was no statistically significant 
difference between the pazopanib/pemetrexed arm and the 
cisplatin/pemetrexed arm for PFS (median PFS, 25.0 versus 
22.9 weeks, respectively; HR = 0.75; 95% CI, 0.43%–1.28%; 
p = 0.26). More patients in the pazopanib/pemetrexed arm (35 
[56%]) had their PFS data censored than those in the cisplatin/
pemetrexed arm (8 [23%]) because of early discontinuation of 
pazopanib/pemetrexed and subsequent initiation of new anti-
cancer therapy due to the SRC recommendation to halt new 
enrolment and terminate treatment with the investigational 
combination (Supplementary Table 1, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A478).
Table 3 summarizes objective responses for both treat-
ment arms. The ORR (complete response + partial response) 
was 23% in the pazopanib/pemetrexed arm and 34% in the 
cisplatin/pemetrexed arm (a difference of –12% with 95% CI, 
–30.6% to 7.2%; p = 0.21).
More patients in the pazopanib/pemetrexed arm had 
unknown responses than those in the cisplatin/pemetrexed 
arm (47% versus 11%, respectively) because of early discon-
tinuation of pazopanib/pemetrexed. At the time enrolment 
was discontinued, eight deaths were reported of 103 patients 
treated: seven in the pazopanib/pemetrexed arm (three consid-
ered disease related) and one in the cisplatin/pemetrexed arm 
(considered disease related). At the time of study closure, 25 
deaths (41%) occurred in the pazopanib/pemetrexed arm and 
12 deaths (35%) occurred in the cisplatin/pemetrexed arm. 
Eighteen deaths (30%) were attributed to disease progression 
in patients in the pazopanib/pemetrexed versus 10 (29%) in 
the cisplatin/pemetrexed arm, and no further data were col-
lected in the study. Available OS data are presented in Table 4 
(see also Supplementary Figure 1, Supplementary Digital 
Patients Randomized
N=106a
XXXX Figure X
This tagline is for information only;
DO NOT PRINT
Paz 800/Pemb
ITT Population
n=62
Randomized not treated
n=1 (protocol criteria not met)
Treated: Paz 800/Pem
Safety Population
n=61
Completed planned
combination treatment
n=13
Treated with Paz monotherapy
after completing combination
n=13
Discontinued Paz n=13
n=9 (Disease progression)
n=4 (Adverse event)
Discontinued Paz 800/Pemc (n=48)
n=19 (Paz/Pem terminatedd)
n=17 (Adverse event)
n = 8 (Disease progression)
n = 3 (Patient decision)
n = 1 (Investigator decision)
Cis/Pem
ITT Population
n=35
Randomized not treated
n=1 (protocol criteria not met)
Treated: Cis/Pem
Safety Population
n=34
Completed planned
combination treatment
n=23
Treated with Paz monotherapy
after disease progression
n=1
Discontinued Paz n=1
n=1 (Disease progression)
Discontinued Cis/Pemc (n=11)
n=5 (Disease progression)
n=3 (Investigator decision)
n=2 (Adverse event)
n=1 (Patient decision)
FIGURE 1.  Consort diagram of the study. aNo 
data were available for two additional patients who 
were randomized but not treated. bNine addi-
tional patients were randomized and eight of these 
patients were treated with pazopanib (600 mg) 
after the implementation of amendment 01, which 
lowered the dose of pazopanib. All patients in this 
group had treatment discontinued as a result of 
amendment 02. cA patient was counted as dis-
continued if they did not complete the planned 
combination treatment with both study treatments. 
dInvestigational combination treatment discontinued 
due to an imbalance in toxicity. Paz, pazopanib; 
Pem, pemetrexed; Cis, cisplatin; Paz 600/Pem, 
pazopanib 600 mg plus pemetrexed; Paz 800/Pem, 
pazopanib 800 mg plus pemetrexed; Cis/Pem, cis-
platin plus pemetrexed; ITT, intent-to-treat.
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Content 2, http://links.lww.com/JTO/A479). A median OS 
could not be estimated based on the collected data before the 
study was closed and survival follow-up ceased; however, the 
Kaplan–Meier estimate of OS based on available data was 
1.22 with 95% CI (0.64–2.33) (p = 0.55).
Safety
Neutropenia, diarrhea, increased alanine aminotrans-
ferase, hypertension, leukopenia, abdominal pain, increased 
aspartate aminotransferase, and decreased weight occurred at 
a higher frequency in patients in the pazopanib/pemetrexed 
arm than those in the cisplatin/pemetrexed arm (Table 5). 
Although the incidence of neutropenia was higher in the 
pazopanib/pemetrexed arm than in the cisplatin/pemetrexed 
arm (66% versus 26%, respectively), the incidence of febrile 
TABLE 1.  Baseline Patient and Disease Characteristics for the 
Intent-to-Treat Population
Characteristic
Pazopanib  
600/ 
Pemetrexed 
(n = 9)
Pazopanib  
800/ 
Pemetrexed 
(n = 62)
Cisplatin/ 
Pemetrexed 
(n = 35)
Age, median (range), yr 66.0 (25–71) 62.0 (40–75) 64.0 (36–74)
  Age <65 yr, n (%) 4 (44) 38 (61) 21 (60)
  Age, ≥65 yr, n (%) 5 (56) 24 (39) 14 (40)
Sex, n (%)
  Female 2 (22) 23 (37) 12 (34)
  Male 7 (78) 39 (63) 23 (66)
Race, n (%)
  African descent 0 1 (2) 0
  Central/South Asian 1 (11) 0 0
  White 8 (89) 61 (98) 35 (100)
History of tobacco use: no. of pack years
  Median 39.0 39.5 22.0
  Range 1–40 1–90 1–182
Unintentional weight loss within 6 mo of starting study, n (%)
  Yes, ≥5% 1 (11) 7 (11) 9 (26)
  Yes, <5% 1 (11) 12 (19) 5 (14)
  No 7 (78) 42 (68) 21 (60)
  Missing 0 1 (2) 0
Stage of disease, n (%)
  IIIb 0 2 (3) 3 (9)
  IV 9 (100) 59 (95) 32 (91)
  Missing 0 1 (2) 0
ECOG performance status
  0 4 39 16
  1 4 22 17
  2 0 0 1
  Missing 1 1 1
Histologic type
  Adenocarcinoma 7 56 27
  Large-cell carcinoma 2 5 4
  Bronchioloalveolar 0 0 4
  Missing 0 1 0
ECOG, Eastern Cooperative Oncology Group.
TABLE 2.   Kaplan–Meier Estimates of Progression-Free 
Survival for the Intent-to-Treat Population
Variable Pazopanib 800/
Pemetrexed
Cisplatin/ 
Pemetrexed
No. of patients 62 35
  Progressed or died, n (%) 27 (44) 27 (77)
  Censored, follow-upa ended, n (%) 35 (56) 8 (23)
Hazard ratiob
  Estimate 0.75
  95% CI 0.43, 1.28
Log-rank p value 0.2647
Estimates (wk)
  Median 25.0 22.9
  95% CI 17.3, 34.1 18.4, 27.7
aFollow-up was classified as ongoing if the patient was still on-study and progression-
free as of their last disease assessment.
bHazard ratios were estimated using a Pike estimator. A hazard ratio <1 indicated a 
lower risk with this treatment compared with the control group.
CI, confidence interval.
TABLE 3.  Confirmed Objective Responses
Response Pazopanib 800/
Pemetrexed  
(n = 62)
Cisplatin/ 
Pemetrexed 
(n = 35)
CR, n (%) 0 0
PR, n (%) 14 (23) 12 (34)
Stable diseasea, n (%) 13 (21) 14 (40)
Progressive disease, n (%) 6 (10) 5 (14)
Unknown, n (%) 29 (47) 4 (11)
Response rate (CR + PR), n (%) 14 (23) 12 (34)
95% CI for % response rate 12.2–33.0 18.6–50.0
aIn order to qualify as an objective response of stable disease, a response of stable 
disease had to be observed at a minimum of 11 weeks.
CR, complete response; PR, partial response; CI, confidence interval.
TABLE 4.  Kaplan–Meier Estimates of Overall Survival for the 
Intent-to-Treat Population
Variable
Pazopanib 800/ 
Pemetrexed
Cisplatin/ 
Pemetrexed
No. of patients 62 35
  Died, n (%) 26 (42) 13 (37)
  Censored, follow-upa ended, n (%) 36 (58) 22 (63)
Hazard ratiob
  Estimate 1.22
  95% CI 0.64, 2.33
Log-rank p value 0.5519
Estimates (wk)
  Median — —
  95% CI 39.3, — 44.1, —
aSurvival data were not collected after the implementation of amendment 03.
bHazard ratios were estimated using a Pike estimator. A hazard ratio <1 indicated a 
lower risk with this treatment compared with the control group.
CI, confidence interval.
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neutropenia was similar in both treatment arms (7% versus 
6%, respectively). Nausea, anemia, constipation, noncardiac 
chest pain, vomiting, and lymphopenia occurred at a higher 
frequency (>10% difference) in patients in the cisplatin/
pemetrexed arm than those in the pazopanib/pemetrexed 
arm. Hypertension occurred in 19 patients (31%) in the pazo-
panib/pemetrexed arm and four patients (12%) in the cispla-
tin/pemetrexed arm. Grade 3 hypertension occurred in five 
patients (8%) in the pazopanib/pemetrexed arm and none in 
the cisplatin/pemetrexed arm. There was no severe (grade 3 or 
above) hemorrhagic events reported in the study.
Grade 3 and grade 4 adverse events occurred at a higher 
frequency in patients in the pazopanib/pemetrexed arm than 
those in the cisplatin/pemetrexed arm, primarily because of a 
higher incidence of hematologic toxicities in the pazopanib/
pemetrexed arm, particularly neutropenia (59% versus 9% in 
the cisplatin/pemetrexed arm) (Table 5).
More patients withdrew from the study because of 
adverse events in the pazopanib/pemetrexed arm than those in 
the cisplatin/pemetrexed arm (34% versus 9%, respectively), 
primarily because of a higher incidence of liver toxicity events 
(elevated alanine aminotransferase and aspartate aminotrans-
ferase), gastrointestinal adverse events (abdominal pain and 
nausea), and fatigue.
At the time enrolment was discontinued, seven deaths 
were reported in the pazopanib/pemetrexed arm of which 
four were not considered related to disease: one was a suicide 
that occurred more than 28 days after pazopanib treatment 
TABLE 5.  Adverse Events Reported by Gradea
Eventc
All Gradesb Grade 3 Grade 4
Pazopanib 800/
Pemetrexed  
(n = 61) n (%)
Cisplatin/ 
Pemetrexed  
(n = 34) n (%)
Pazopanib 800/
Pemetrexed  
(n = 61) n (%)
Cisplatin/ 
Pemetrexed  
(n = 34) n (%)
Pazopanib 800/
Pemetrexed  
(n = 61) n (%)
Cisplatin/ 
Pemetrexed  
(n = 34) n (%)
Nonhematologic
  Fatigue/astheniad 32 (52) 20 (59) 4 (7) 1 (3) 0 0
  Diarrhea 25 (41) 6 (18) 3 (5) 1 (3) 0 0
  Nausea 25 (41) 21 (62) 3 (5) 2 (6) 0 0
  Hypertension 19 (31) 4 (12) 5 (8) 0 0 0
  Increased alanine aminotransferase 16 (26) 1 (3) 4 (7) 1 (3) 2 (3) 0
  Vomiting 15 (25) 13 (38) 2 (3) 0 0 0
  Epistaxis 14 (23) 8 (24) 0 0 0 0
  Abdominal pain 13 (21) 3 (9) 5 (8) 0 1 (2) 0
  Decreased appetite 13 (21) 7 (21) 2 (3) 0 0 0
  Mucosal inflammation/stomatitisd 13 (21) 7 (21) 3 (5) 0 0 0
  Rash 11 (18) 5 (15) 1 (2) 0 0 0
  Dyspnea 10 (16) 9 (26) 1 (2) 1 (3) 1 (2) 0
  Abdominal pain upper 9 (15) 4 (12) 0 0 0 0
  Increased aspartate aminotransferase 9 (15) 1 (3) 3 (5) 1 (3) 1 (2) 0
  Constipation 9 (15) 11 (32) 2 (3) 0 0 1 (3)
  Dizziness 9 (15) 4 (12) 0 0 0 0
  Decreased weight 9 (15) 2 (6) 0 0 0 0
  Pyrexia 8 (13) 7 (21) 0 0 0 0
  Increased blood bilirubin 6 (10) 0 2 (3) 0 0 0
  Cough 6 (10) 5 (15) 0 0 0 0
  Increased lacrimation 6 (10) 4 (12) 0 0 0 0
  Noncardiac chest pain 3 (5) 6 (18) 1 (2) 0 0 0
  Decreased creatinine renal clearance 1 (2) 4 (12) 0 0 0 0
  Tinnitus 1 (2) 4 (12) 0 0 0 0
Hematologic
  Neutropenia 40 (66) 9 (26) 21 (34) 3 (9) 15 (25) 0
  Leukopenia 14 (23) 3 (9) 6 (10) 0 3 (5) 0
  Thrombocytopenia 9 (15) 7 (21) 5 (8) 1 (3) 3 (5) 0
  Anemia 8 (13) 11 (32) 1 (2) 1 (3) 1 (2) 0
  Lymphopenia 8 (13) 8 (24) 4 (7) 0 1 (2) 1 (3)
aOnly adverse events reported in at least 10% of patients in either the pazopanib/pemetrexed or cisplatin/pemetrexed arm were listed.
bTotal no. of adverse events of any grade reported during all treatment phases.
cAdverse events were listed in descending order based on the incidence in the pazopanib/pemetrexed arm.
dNo patient reported both adverse events.
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was discontinued and three deaths were fatal serious 
adverse events (ileus, tumor embolism, and bronchopneu-
monia/sepsis; see Supplementary Table 2, Supplementary 
Digital Content 3, http://links.lww.com/JTO/A480). The 
death reported in the cisplatin/pemetrexed arm at this time 
was considered disease related. At the time of study closure, 
the incidence of deaths not attributed to the disease under 
study was higher in the pazopanib/pemetrexed arm than 
in the cisplatin/pemetrexed arm (7 [12%] versus 2 [6%], 
respectively). Nevertheless, no specific fatal toxicity was 
observed that could explain the imbalance (Supplementary 
Table 2, Supplementary Digital Content 3, http://links.lww.
com/JTO/A480).
DISCUSSION
Although this study was discontinued early due to unex-
pected toxicity, it demonstrated that the combination of an anti-
VEGFR-TKI and a cytotoxic drug had some antitumor activity.
The initial goal of this study was to determine whether a 
platinum agent like cisplatin could be replaced by pazopanib. 
With the limitation of the available data from this study, it can-
not be excluded that the pazopanib/pemetrexed combination 
has activity with a HR for PFS of 0.75 (despite the proportion 
of censored data); however, the observed trade-off between 
activity and toxicity does not allow further clinical exploration 
for this combination.
The combination of pazopanib and pemetrexed in this 
study was not tolerated; there was a higher incidence of severe 
and fatal toxicities and toxicity leading to treatment discon-
tinuation with the pazopanib/pemetrexed combination. In a 
previously conducted phase Ib study of this combination,25 
in patients with previously treated advanced solid tumors, the 
incidence of nonhematologic toxicity was consistent with that 
observed with each individual agent; however, a higher rate 
of hematologic toxicity (primarily brief reversible neutropenia) 
was observed with the combination. The incidence of neutro-
penia was considered to have been influenced by the extent of 
prior treatment (72% of patients received the combination as at 
least third-line therapy). The first clear signal of toxicity identi-
fied in this study with the pazopanib/pemetrexed combination 
in a population that had not received any prior treatment was 
again an increased incidence of severe, short-lasting neutrope-
nia despite all patients having received the required premedi-
cation for pemetrexed to counteract hematologic toxicity. This 
toxicity signal was accompanied by an increased incidence of 
treatment discontinuations due to adverse events other than 
neutropenia that was suggestive of a broader toxicity.
Although TKIs are generally better tolerated than 
cytotoxic chemotherapy, side effects develop in many 
patients from on-target and off-target effects, which require 
aggressive management to maintain patient compliance, 
optimize therapy, and avoid potentially life-threatening 
consequences. In this study, monthly safety reviews by an 
independent SRC facilitated prompt action to be taken with 
the emerging safety profile of the pazopanib/pemetrexed 
combination; initially, a dose reduction of pazopanib was 
implemented and shortly afterward enrolment was halted 
and treatment terminated.
Patients with advanced renal cell carcinoma and 
advanced soft-tissue sarcoma who have received prior che-
motherapy form the basis for the safety profile of pazopanib 
monotherapy.14 Experience with pazopanib monotherapy in 
NSCLC is limited; however, preliminary data suggested that 
the safety profile of pazopanib monotherapy in NSCLC was 
similar to the safety profile in patients with advanced renal 
cell carcinoma and advanced soft-tissue sarcoma.15 The safety 
profile of pemetrexed has been well established with folic 
acid/vitamin supplementation.31
At the time this study was initiated, experience with 
VEGFR-TKIs in combination with chemotherapy in the first-
line setting was limited. Randomized studies with sorafenib,32 
cediranib,33 and motesanib34 in combination with platinum-
based doublets were ongoing, and preliminary reports of 
imbalances in toxicity and an increased risk of mortality with 
these triplet regimens were emerging. At that time, a clear 
relationship to specific toxicities or a specific mechanistic 
explanation for these observations remained to be defined, 
although several risk factors had been suggested, including 
squamous cell histology, prior hemoptysis, and the presence 
of central nervous system metastases. Nevertheless, in the 
second-line setting of NSCLC, it had been previously shown 
that the doublet combination of single cytotoxic agents and a 
VEGFR-TKI, such as vandetanib, was safe and had demon-
strated antitumor activity.35,36
For the pazopanib/pemetrexed combination, pharma-
cokinetic analysis carried out in a phase Ib study25 did not 
indicate that a pharmacokinetic interaction could be respon-
sible for the increased toxicity seen with the combination. 
The exposure (area under the concentration–time curve) and 
clearance of pemetrexed were unchanged by the administra-
tion of pazopanib, even though a small increase of 22% in 
the maximum concentration of pemetrexed was reported. In 
another study, single-agent pemetrexed was well tolerated 
when administered at high doses (600–1400 mg/m2) with vita-
min supplementation in patients with locally advanced or met-
astatic cancer, despite an increase in pemetrexed exposure.37 
Therefore, the increased toxicity observed with the combina-
tion of pazopanib and pemetrexed in this study is likely inde-
pendent of pemetrexed exposure.
In addition, an exploratory evaluation of three biomark-
ers of folic acid and vitamin B12 metabolism (cystathionine, 
homocysteine, and methylmalonic acid) was initiated using 
samples collected during the phase Ib study to explore the 
possibility that increased neutropenia resulted from pazopanib 
interfering with vitamin metabolism; however, there was no 
relationship between pazopanib, pemetrexed, the vitamin bio-
markers, and grade 3/4 neutropenia, suggesting that folic acid 
and vitamin B12 insufficiencies do not seem to explain the rel-
atively high rate of hematologic toxicity with the pazopanib/
pemetrexed combination.25
Of interest, recent data have emerged suggesting that 
even the doublet combination of sunitinib and pemetrexed38 
and erlotinib and pemetrexed39 in second-line treatment 
of NSCLC is similarly associated with a high level of both 
hematologic and nonhematologic toxicity, indicating that 
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combinations of a TKI and pemetrexed should be undertaken 
only with great caution.
In conclusion, this study, despite evidence of activity, 
demonstrated that the combination of pazopanib and peme-
trexed in NSCLC had unacceptable levels of toxicity. The 
combination of pazopanib and pemetrexed will not be evalu-
ated further; however, this does not rule out the possibility 
for further investigation of pazopanib alone or in combination 
with other agents in the treatment of advanced NSCLC.
Because two thirds of patients randomized to the inves-
tigational arm lost the chance to receive the standard treat-
ment, in further studies, pazopanib should be evaluated as a 
combination with a platinum doublet in the first-line setting, 
as a combination with docetaxel in the second-line setting, or 
as a monotherapy in the third-line setting.
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